IDEXX Laboratories, Inc. $IDXX Stock Sold by Villere ST Denis J & Co. LLC

Villere ST Denis J & Co. LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.4% in the third quarter, HoldingsChannel.com reports. The fund owned 31,598 shares of the company’s stock after selling 2,145 shares during the quarter. IDEXX Laboratories accounts for 1.7% of Villere ST Denis J & Co. LLC’s holdings, making the stock its 24th biggest position. Villere ST Denis J & Co. LLC’s holdings in IDEXX Laboratories were worth $16,500,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Arlington Trust Co LLC grew its stake in IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the period. Bell Investment Advisors Inc lifted its stake in IDEXX Laboratories by 45.5% in the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after buying an additional 20 shares during the period. Annis Gardner Whiting Capital Advisors LLC lifted its stake in IDEXX Laboratories by 21.4% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after buying an additional 21 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock worth $202,000 after buying an additional 23 shares in the last quarter. Finally, Carnegie Investment Counsel boosted its holdings in shares of IDEXX Laboratories by 1.3% during the 1st quarter. Carnegie Investment Counsel now owns 2,000 shares of the company’s stock worth $1,124,000 after buying an additional 25 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 4.5%

NASDAQ IDXX opened at $706.65 on Tuesday. The company has a market cap of $55.68 billion, a price-to-earnings ratio of 47.65 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The business has a 50 day moving average price of $549.78 and a 200-day moving average price of $573.40. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the business earned $3.22 EPS. IDEXX Laboratories’s quarterly revenue was up 9.9% compared to the same quarter last year. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on IDXX shares. Jefferies Financial Group reduced their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Leerink Partners cut their target price on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. UBS Group lifted their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $717.27.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, insider Jonathan Mazelsky sold 25,140 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total transaction of $17,678,196.60. Following the completion of the sale, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. The trade was a 23.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the sale, the executive vice president directly owned 7,169 shares of the company’s stock, valued at approximately $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,428 shares of company stock worth $28,567,934 in the last ninety days. 0.79% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices.

The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.